Abstract
The BCR-ABL oncogene encodes an in-frame fusion protein containing N-terminal sequences derived from Bcr and C-terminal sequences derived from Abl. Bcr contains a centrally located Rho-specific guanine nucleotide exchange factor (RhoGEF) domain that is retained within p210 Bcr-Abl. Although this domain is subject to autoinhibition in the context of Bcr, here we show that it is constitutively activated in p210 Bcr-Abl. p210 Bcr-Abl can stimulate RhoA activation independently of its tyrosine kinase activity, and mutations within the RhoGEF domain that are predicted to eliminate RhoGEF activity inhibit RhoA activation. The RhoGEF mutant of p210 Bcr-Abl does not affect the tyrosine kinase activity of the molecule, nor the ability of p210 Bcr-Abl to interact with XPB through the RhoGEF domain. Despite retaining normal levels of tyrosine kinase activity, the RhoGEF mutant of p210 Bcr-Abl is impaired in transforming activity as measured by anchorage-independent growth. However, the mutant is still able to confer the phenotype of growth factor independence in myeloid cells, suggesting that some, but not all parameters of p210 Bcr-Abl transformation, are dependent upon a catalytically active RhoGEF domain. Collectively, these observations identify a gain-of-function activity attributable to the RhoGEF domain of p210 Bcr-Abl that is required to support the transformed phenotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S et al. (2002). Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 277: 12437–12445.
Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch GM . (1995). Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci USA 92: 10282–10286.
Daley GQ, Baltimore D . (1998). Transformation of an interleukin 3-dependent hematopoietic cell-line by the chronic myelogenous leukemia-specific p210 Bcr-Abl protein. Proc Natl Acad Sci USA 85: 9312–9316.
Han J, Das B, Wei W, Van Aelst L, Mosteller RD, Khosravi-Far R et al. (1997). Lck regulates Vav activation of members of the Rho family of GTPases. Mol Cell Biol 17: 1346–1353.
Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N . (2003). Differential interaction and activation of Rho family GTPases by p210bcr−abl and p190bcr−abl. Oncogene 22: 6445–6454.
Korus M, Mahon GM, Cheng L, Whitehead IP . (2002). p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr. Oncogene 21: 4601–4612.
Lugo TG, Pendergast AM, Muller AJ, Witte ON . (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082.
Lugo TG, Witte ON . (1989). The Bcr-Abl oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 9: 1263–1270.
Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T et al. (2003). The c-Myc oncoprotein interacts with Bcr. Curr Biol 13: 437–441.
McWhirter JR, Wang JY . (1991). Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11: 1553–1565.
McWhirter JR, Wang JY . (1993). An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12: 1533–1546.
Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR et al. (1991). BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11: 1785–1792.
Olabisi OO, Mahon GM, Kostenko EV, Liu Z, Ozer HL, Whitehead IP . (2006). Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 66: 6250–6257.
Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66: 161–171.
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175–185.
Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK et al. (2004). Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 64: 5322–5331.
Renshaw MW, McWhirter JR, Wang JY . (1995). The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 15: 1286–1293.
Ridley AJ . (1995). Rho-related proteins: actin cytoskeleton and cell cycle. Curr Opin Genet Dev 5: 24–30.
Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA et al. (1997). BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100: 46–57.
Shtivelman E, Lifshitz B, Gale RP, Canaani E . (1985). Fused transcript of abl and bcr genes in chronic melogenous leukaemia. Nature 315: 550–554.
Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M et al. (1998). BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci USA 95: 11858–11862.
Takeda N, Shibuya M, Maru Y . (1999). The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 96: 203–207.
ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N et al. (1994). Cellular interactions of CRKL, an SH2–SH3 adaptor protein. Cancer Res 54: 2563–2567.
Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS . (2002). BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99: 4122–4130.
Whitehead IP, Campbell S, Rossman KL, Der CJ . (1997). Dbl family proteins. Biochim Biophys Acta 1332: F1–F23.
Acknowledgements
This work was supported by Public Health Service grant CA097066 (IPW) from the National Cancer Institute and AG04821 (HLO) from the National Institute of Aging. PL Rodriguez and NL Pannucci are recipients of fellowships from the New Jersey Commission for Cancer research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Sahay, S., Pannucci, N., Mahon, G. et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 27, 2064–2071 (2008). https://doi.org/10.1038/sj.onc.1210841
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210841
Keywords
This article is cited by
-
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis
Leukemia (2017)
-
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Nature Communications (2017)
-
ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells
Molecular Cancer (2016)
-
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression
Leukemia (2013)
-
Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity
Blood Cancer Journal (2013)